Segment Information (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Segment Reporting Information, by Segment

Significant segment expenses which are regularly reported to the CODM for purposes of making decisions regarding the allocation of resources are included within the table below and are reconciled to net loss (in thousands):


	Year Ended December 31,
	2025			2024
Total Revenue	$	7,145		$	25,983
Less:
ADC assets - research and development expenses		59,092			6,000
ADC assets - contract manufacturing expenses		26,703			—
FYARRO - research and development expenses		5,168			34,338
FYARRO - contract manufacturing expenses		—			10,692
FYARRO - commercial and marketing expenses		294			2,130
Finance and accounting expenses (1)		9,349			11,758
Legal expenses		5,815			7,437
Other segment items (2)		(78,680	)		17,319
Net loss	$	(20,596	)	$	(63,691	)

(1)

Finance and accounting expenses primarily include shared-based compensation, insurance, salaries and wages, and other outside consulting services.

(2)

Other segment items primarily include other SGA departmental expenses, cost of sales, interest expense, other income, foreign exchange loss, and gain on sale of business.

Whitehawk Therapeutics, Inc. 10-K